FSSAI files three cases against Nestlé India over infant nutrition compliance

FSSAI has initiated three adjudication cases against Nestlé India, citing alleged prohibited promotional claims for infant-food products and a follow-up formula sample that did not meet prescribed biotin content after re-analysis.

— Source publishedFri, 18 Sept, 2026, 13:38 IST·First seen Fri, 18 Sept, 2026, 13:45 IST·Source The Hindu BusinessLine

What happened

FSSAI has filed three adjudication cases against Nestlé India over alleged prohibited promotional claims for infant-food products and a follow-up formula sample

Key facts

  • 3 separate adjudication cases
  • Regulation 4(2) of FSS (Foods for Infant Nutrition) Regulations, 2020
  • Section 3 of the IMS Act, 1992
  • 5 HMOs

Why this matters

The regulatory action underscores the need for rigorous compliance diligence around infant-food claims, nutrient specifications and post-launch quality systems in FMCG transactions.

What to watch

  • FSSAI adjudication notices, hearing dates, penalty orders, or directions involving product withdrawal, relabelling, or advertising restrictions.
  • Whether the biotin finding is confined to one follow-up sample or expands to additional batches, products, or manufacturing sites.
  • Nestlé India's public disclosure of provisions, recalls, sales effects, or changes to infant-nutrition marketing practices.
  • Further inspections or enforcement actions affecting other infant-formula manufacturers, indicating a category-wide crackdown.
  • Media coverage, pediatrician commentary, consumer complaints, and changes in retailer/distributor stocking behavior.
  • Issue a detailed compliance response distinguishing marketing-claim allegations from product-safety and nutrient-specification matters.
  • Review and withdraw or modify potentially non-compliant infant-nutrition promotional materials across digital, retail, distributor, and healthcare-professional channels.
  • Conduct broader batch testing and supplier/process audits for micronutrient consistency, especially biotin, and document corrective actions to FSSAI.
  • Prepare for possible penalties, label or claim revisions, and enhanced regulatory reporting requirements.
  • Increase stakeholder communication with parents, pediatricians, retailers, and distributors to contain trust erosion.